Meningitis News and Research

Latest Meningitis News and Research

Early retroviral use best for AIDS patients with serious complications

HIV-positive patients who don't seek medical attention until they have a serious AIDS-related condition can reduce their risk of death or other complications by half if they get antiretroviral treatment early on, according to a new multicenter trial led by researchers at the Stanford University School of Medicine.

17 May 2009

Early use of antiretroviral treatment improves survival rate of HIV patients

A clinical study, led by researchers from University College Dublin, Ireland, and Stanford University, California, USA, with international collaborators, demonstrates that mortality rates of HIV patients can be almost halved when early antiretroviral (ARV) therapy is added to the treatment of AIDS-related opportunistic infections (OIs) such as pneumonia, meningitis or other serious bacterial infections.

17 May 2009

Break through in the treatment of bacterial meningitis

It can take just hours after the symptoms appear for someone to die from bacterial meningitis. Now, after years of research, experts at The University of Nottingham have finally discovered how the deadly meningococcal bacteria is able to break through the body's natural defence mechanism and attack the brain.

13 May 2009

Contamination of seeds for alfalfa sprouts linked to salmonella

The U.S. Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC) have recommended that consumers not eat raw alfalfa sprouts, including sprout blends containing alfalfa sprouts, until further notice because the product has been linked to Salmonella serotype Saintpaul contamination.

26 Apr 2009

UK cases of bacterial meningitis in children at a record low

Cases of bacterial meningitis in children are at a record low thanks to NHS immunisation programmes, Health Secretary Alan Johnson announced.

26 Apr 2009

Key genetic mechanism a potential key to new class of antibiotics

Researchers have determined the structure of a key genetic mechanism at work in bacteria, including some that are deadly to humans, in an important step toward the design of a new class of antibiotics, according to an accelerated publication that appeared online today as a "paper of the week" in the Journal of Biological Chemistry.

20 Apr 2009

Intercell starts trial for Streptococcus pneumoniae vaccine candidate

Intercell AG has announced that a Phase I clinical trial with the company's vaccine candidate IC47 to prevent disease caused by the bacterium Streptococcus pneumoniae has started.

8 Apr 2009

Spinal taps carry higher risks for infants and elderly, study shows

An X-ray-guided spinal tap procedure fails more than half of the time in young infants and should be used sparingly, if at all, for those patients, according to a new study done by researchers at Wake Forest University School of Medicine.

19 Mar 2009

Universal vaccination associated with decreased Canadian cases of most deadly strain of meningitis

Universal childhood vaccination against meningococcal C appears to reduce Canadian incidence of the most deadly strain of bacterial meningitis, reports new research published in the March issue of The Pediatric Infectious Disease Journal.

2 Mar 2009

Wyeth's Prevenar vaccine for pneumococcal disease registered in Russia

Wyeth announced today that its 7-valent pneumococcal conjugate vaccine, Prevenar (Pneumococcal saccharide conjugated vaccine, Adsorbed), has been registered by the Russian Ministry of Health and Social Development (Roszdravnadzor) and is expected to be commercially available later this year.

2 Mar 2009

Bacteria-killing enzyme cures mice with fatal pneumonia

Before the advent of antibiotics, pneumonia claimed so many lives - and was so feared - that it was called the "captain of the ship of death."

1 Mar 2009

Meningitis bacteria dress up as human cells to evade our immune system

The way in which bacteria that cause bacterial meningitis mimic human cells to evade the body's innate immune system has been revealed by researchers at the University of Oxford and Imperial College London.

20 Feb 2009

Many neglected diseases lacking research funding

The first comprehensive survey of global spending on neglected disease R&D, published in this week's PLoS Medicine , finds that just over $US 2.5 billion was invested into R&D of new products in 2007, with three diseases-HIV/AIDS, TB, and malaria-receiving nearly 80% of the total

5 Feb 2009

Pediatric vaccine propels sharp drop in meningitis cases

A pediatric vaccine with University of Rochester roots has proven to be highly successful at reducing cases of bacterial meningitis across all age groups.That is the conclusion of a seven-year study, the results of which appeared today in the New England Journal of Medicine.

14 Jan 2009

Australian discovers gene for deadly Kawasaki disease

An Australian researcher has identified genes which could make some children more susceptible to the deadly Kawasaki disease - an inflammatory condition in young children that can damage blood vessels.

12 Jan 2009

New safety advice on wheat-based infant formula could prevent infant suffering

Wheat-based infant follow-on formulas are better reconstituted with fruit juice and should be stored in the fridge at 4°C to prevent growth of meningitis bacteria, according to recent research.

6 Jan 2009

Many babies with simple febrile seizures can avoid spinal tap

When babies develop a fever high enough or abrupt enough to cause a seizure, frightened parents often rush them to the emergency room, where their workup frequently includes a lumbar puncture (spinal tap) to rule out bacterial meningitis.

6 Jan 2009

Phase 3 trial begins for Gammagard liquid plus rHuPH20 in primary immunodeficiency patients

Baxter International Inc. and Halozyme Therapeutics, Inc. gas announced the start of a Phase 3 clinical trial of Baxter's Gammagard Liquid [Immune Globulin Intravenous] 10% (IGIV), marketed as KIOVIG in the European Union, with Halozyme's recombinant human hyaluronidase enzyme (rHuPH20, Enhanze Technology) for the treatment of primary immunodeficiency (PID).

From Baxter International Inc. 5 Jan 2009

Vaccine against malaria could be ready in 5 years

Malaria kills more than one million people every year so the news that an effective vaccine could be available within five years is more than welcome.

9 Dec 2008